Trenton, NJ - On the heels of the state’s commanding presence at BIO International 2015, New Jersey’s dominance in biotechnology was validated with a top ranking nationally in the Biotech Growth Potential category in Business Facilities Magazine’s Annual Rankings Report released today.
|
Philadelphia, PA – The Biotechnology Industry Organization (BIO) released “Bioscience Economic Development in the States: Legislation and Job Creation Best Practices” today at the 2015 BIO International Convention. The Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.
Philadelphia, PA. – The Biotechnology Industry Organization (BIO) announced its selection of New Jersey State Assemblywoman Pamela Lampitt (6th District) as a state Legislator of the Year for 2015. Assemblywoman Lampitt is the prime sponsor of A-2477, which authorizes the prescription and dispensing of biosimilar products in New Jersey. Assemblywoman Lampitt received this honor during the 2015 BIO International Convention.
Trenton, NJ - New Jersey will showcase its business strengths in the life science industry to a global audience next week at the world’s largest biotechnology conference, BIO International, being held at the Philadelphia Convention Center on June 15-18.
Union, NJ - The Institute for Life Science Entrepreneurship (ILSE), a non-profit translational science research integrator, accelerator and incubator, and ATCC, the premier global biological materials resource and standards organization, announced today a collaboration to establish The ATCC Center for Translational Microbiology at ILSE (the “Center”). The focus of the Center will be on key challenges identified by both ATCC and ILSE in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics and the microbiome.
New Brunswick, NJ - Joachim Messing, director of Rutgers University’s Waksman Institute of Microbiology, has been selected to membership in the National Academy of Sciences, one of the highest honors an American scientist or engineer can achieve. Messing, who is considered to be among the world’s top experts in molecular genetics, was among 84 new members elected and recognized this year for their distinguished and continuing achievements in original research.
Washington D.C. – According to Thomas Peter Stossel of the American Enterprise Institute, “Over the years I have practiced medicine, U.S. longevity has increased by a decade, deaths from the commonest killer, cardiovascular disease, have dropped by 60 percent, and cancer deaths, the second most prevalent cause, are at an all-time low. HIV-infected individuals, once doomed, live normal albeit medicated lives. Arthritis sufferers previously condemned to pain, crutches and wheelchairs enjoy relative comfort and mobility. Unfortunately, three pernicious myths conspire to undermine such optimism.”
Trenton, NJ – The third annual, New Jersey Life Sciences Week runs from April 20 – 24 and events will be held all over the state. Each day during the week features activities throughout the State which will showcase the contributions that New Jersey's life science community members are making to advance medical research, support patients, maximize our amazing talent pool and contribute to the State's economy.
Bethesda, MD – The Federation of American Societies for Experimental Biology (FASEB) has released new interactive factsheets summarizing federal science funding in states and U.S. congressional districts. This is the only resource to feature up-to-date information about federal science funding at the district level and make it accessible to the general public.
Princeton, NJ - Mark Esposito stood before a panel of judges at the Keller Center's 10th annual Innovation Forum on Feb. 25 and made a bold statement — a leap forward in cancer treatment is close at hand. "The problem is we're treating the wrong disease," said Esposito, a Princeton University graduate student in molecular biology. Esposito took the top prize at the Innovation Forum, an event for University researchers to present potentially marketable discoveries, with his pitch for a method to stop the spread of cancer, called metastasis.
River Edge, NJ - Nephros, Inc., a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of chronic renal failure patients, announced today that the Renal Research Institute (“RRI”) is conducting an evaluation of the company’s hemodiafiltration (“HDF”) system. The Nephros HDF system is comprised of Nephros’ patented OLpur MD220 Mid-Dilution Hemodiafilter and OLpur H2H Hemodiafiltration Module. The module is designed for use with a standard hemodialysis machine to enable hemodiafiltration treatment of patients with chronic renal failure.
Summit, NJ - These are exciting times for Celgene and promising times for the patients we serve. We continue to deliver on multiple opportunities, translating the potential of transformational science into disease-altering and life-enhancing innovative medicines with the goal of helping patients with critical unmet medical needs worldwide live longer and better lives. This dedication to patients is aligned with our corporate vision, mission and values and reflects our unwavering commitment to put patients first. By advancing the course of healthcare through bold scientific pursuits and medical innovation we are making it possible for societies to progress and economies to prosper.
Princeton, NJ - Five innovative projects have been awarded support through Princeton University's Dean for Research innovation funds. According to Catherine Zandonella of the Office of the Dean for Research, this fund is in its second year, the program enables faculty members to pursue bold new ideas. "Three projects in the natural sciences will receive $200,000 each over two years and will explore original, early-stage ideas that could serve as the basis of a larger research initiative. In addition, two collaborations with biomedical engineering and neuroscience companies will receive $100,000 each for the first year; Princeton will match each company's contribution of up to $75,000 in the second year."
|
Do not miss a single innovative moment and sign up for our newsletter!
|
